Video

Dr. Spaggiari on Surgical Strategies to Improve Liver Remnants in CRC With Liver Metastases

Mario Spaggiari, MD, discusses surgical strategies to improve liver remnants in colorectal cancer with liver metastases.

Mario Spaggiari, MD, transplant surgeon, Division of Transplantation, University of Illinois Health, discusses surgical strategies to improve liver remnants in colorectal cancer (CRC) with liver metastases.

The liver remnant, or how much liver is left after surgery, is an important aspect of a successful surgical resection for patients with CRC and liver metastases, Spaggiari says. As such, different surgical approaches can be utilized to increase the size of non-malignant liver in preparation for surgery, including portal vein embolization. With this strategy, the liver can be restaged after 2 to 3 weeks following portal vein embolization and then the patient can be reassessed for surgery.

Additionally, aggressive surgical procedures that can increase the size of the liver in a shorter period can be utilized if the patient requires more immediate surgery, Spaggiari explains. For example, utilizing surgery in combination with interventional radiology allows for a patient to undergo a large surgery with a significantly increased liver remnant within a period of 7 to 15 days, Spaggiari concludes.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine